Lorenza Rimassa

机构：Humanitas University, IRCCS Humanitas Research Hospital · ORCID：0000-0001-9957-3615

发表论文 763 篇 · 总被引 23717 次 · h-index 70

代表论文

• Cholangiocarcinoma 2026: status quo, unmet needs and priorities (2025 · Nature Reviews Gastroenterology & Hepatology · 被引 50)
• Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers (2025 · Liver International · 被引 9)
• Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer (2025 · JAMA Oncology · 被引 7)
• Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis (2025 · Liver Cancer · 被引 3)
• Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis (2025 · ESMO Open · 被引 3)
• A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma (2026 · Journal of Hepatology · 被引 2)